Home » Stocks » SNOA

Sonoma Pharmaceuticals, Inc. (SNOA)

Stock Price: $6.61 USD -0.13 (-1.93%)
Updated December 1, 10:27 AM EST - Market open

Stock Price Chart

Key Info

Market Cap 13.50M
Revenue (ttm) 20.79M
Net Income (ttm) -2.10M
Shares Out 2.04M
EPS (ttm) -1.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $6.61
Previous Close $6.74
Change ($) -0.13
Change (%) -1.93%
Day's Open 6.74
Day's Range 6.61 - 6.77
Day's Volume 7,062
52-Week Range 3.71 - 9.80

More Stats

Market Cap 13.50M
Enterprise Value 11.20M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 2.04M
Float n/a
EPS (basic) -1.38
EPS (diluted) -1.18
FCF / Share -3.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6,957
Short Ratio 0.40
Short % of Float n/a
Beta 0.90
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 0.65
PB Ratio 1.22
Revenue 20.79M
Operating Income -3.00M
Net Income -2.10M
Free Cash Flow -6.70M
Net Cash 2.30M
Net Cash / Share 1.13
Gross Margin 39.21%
Operating Margin -14.44%
Profit Margin -10.10%
FCF Margin -32.20%
ROA -14.98%
ROE -26.47%
ROIC -20.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$9.00*
Low
9.00
Current: $6.61
High
9.00
Target: 9.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue18.9418.9716.6612.839.3713.8513.6715.4512.749.75
Revenue Growth-0.18%13.88%29.89%36.89%-32.37%1.36%-11.55%21.25%30.65%-
Gross Profit8.338.887.315.672.657.298.4010.748.716.14
Operating Income-3.10-11.26-14.50-12.97-14.71-6.66-6.05-3.37-6.47-7.51
Net Income-2.95-11.80-14.339.27-10.16-8.203.74-5.43-7.33-7.95
Shares Outstanding1.480.920.500.470.370.210.150.110.090.08
Earnings Per Share-1.99-12.77-28.4919.80-27.81-38.2524.30-58.50-84.15-94.50
Operating Cash Flow-4.59-11.72-12.44-8.17-8.75-6.69-4.891.15-4.03-4.43
Capital Expenditures-0.21-0.10-0.19-0.39-0.35-0.14-0.50-0.26-0.34-0.17
Free Cash Flow-4.80-11.82-12.63-8.56-9.09-6.83-5.390.89-4.37-4.60
Cash & Equivalents3.693.6910.0717.467.476.145.487.903.354.37
Total Debt1.480.480.550.410.110.090.151.943.242.55
Net Cash / Debt2.213.219.5117.057.366.055.335.970.111.83
Assets14.5614.4519.2125.4613.8015.0520.7912.577.848.66
Liabilities5.863.963.884.033.662.998.738.488.716.96
Book Value8.7110.4915.3321.4310.1412.0512.064.08-0.871.70
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Sonoma Pharmaceuticals, Inc.
Country United States
Employees 19
CEO Amy M. Trombly

Stock Information

Ticker Symbol SNOA
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: SNOA
IPO Date January 25, 2007

Description

Sonoma Pharmaceuticals, develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as Loyon for the management of skin scaling. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.